Form 4: Theravance Biopharma Insider Acquires Shares

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, acquired 18,750 ordinary shares.

Summary

• Rhonda Farnum, Senior Vice President of Commercial & Medical Affairs at Theravance Biopharma, Inc., acquired 18,750 ordinary shares on April 1, 2026.
• The acquisition was made at a price of $0 per share, indicating it was likely a grant or award.
• Following this transaction, Farnum beneficially owns 251,449 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider share acquisition without providing new financial or strategic information.

Positives

• Insider acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 18,750 shares by a key executive demonstrates continued commitment to the company.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as this share acquisition by a senior executive, are often closely watched by investors as potential indicators of management's view on the company's valuation and future performance within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders may view this insider acquisition positively, interpreting it as a sign of confidence from a key executive.
• Employees may see this as a positive signal about the company's stability and future prospects.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Trading, Share Acquisition, Rhonda Farnum, SEC Filing